Agency Information Collection Activities: Submission for OMB Review; Comment Request, 37912 [2012-15414]

Download as PDF 37912 Federal Register / Vol. 77, No. 122 / Monday, June 25, 2012 / Notices would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Phase II Trials in Lung Disease. Date: July 12, 2012. Time: 8:30 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Renaissance Washington DC, Dupont Circle, 1143 New Hampshire Avenue NW., Washington, DC 20037. Contact Person: Stephanie L Constant, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7189, Bethesda, MD 20892, 301– 443–8784, constantsl@nhlbi.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) Dated: June 14, 2012. Jennifer S. Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 2012–15472 Filed 6–22–12; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Submission for OMB Review; Comment Request Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (240) 276–1243. Project: Enhancing Substance Abuse Treatment Services To Address Hepatitis Infection Among Intravenous Drug Users Hepatitis Testing and Vaccine Tracking Form (OMB No. 0930–0300)—Reinstatement and Extension The Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center Substance Abuse Treatment (CSAT), is responsible for the Hepatitis Testing and Vaccine Tracking Form for the prevention of Viral Hepatitis in patients in designated Opioid Treatment Programs (OTPs). There are no changes to the form or added burden. This form allows SAMHSA/CSAT to collect essential Clinical information that will be used for quality assurance, quality performance and product monitoring on approximately 264 Rapid Hepatitis C Test kits and 10,628 doses of hepatitis vaccine (Twinrix, HAV, or HBV). The above kits and vaccines will be provided to designated OTPs serving the minority population in their communities. The information collected on the Form solicits and reflect the following information: • Demographics (age, gender, ethnicity) of designated OTP site • History (Screening) of Hepatitis C exposure • Results of Rapid Hepatitis C Testing (Kit) and Follow-up information • Service Provided (type of vaccine given) Divalent vaccine (Twinrixcombination HAV and HBV) or Monovalent vaccine (HAV and/or HBV) • Substance Abuse Treatment Outcomes (Information regarding the beginning, continuing or completion of vaccination series) • Type of Referral Services Indicated (i.e., Gastroenterology, TB; Mental Health, Counseling, Reproductive/ Prenatal, etc.) This program is authorized under Section 509 of the Public Health Service (PHS) Act [42 U.S.C. 290bb–2]. The form increases the screening and reporting of viral hepatitis in high risk minorities in OTPs. The information collected allows SAMHSA to address the increased morbidity and mortality of hepatitis in minorities being treated for drug addiction. The SAMHSA/CSAT Hepatitis Testing and Vaccine Tracking Form supports quality of care, provide minimum but adequate clinical and product monitoring, and provide appropriate safeguards against fraud, waste and abuse of Federal funds. The table below reflects the annualized hourly burden. Responses/ respondent Burden hours Total burden hours 50,000 erowe on DSK2VPTVN1PROD with NOTICES Number of respondents screened 1 0.05 2,500 Written comments and recommendations concerning the proposed information collection should be sent by July 25, 2012 to the SAMHSA Desk Officer at the Office of Information and Regulatory Affairs, Office of Management and Budget (OMB). To ensure timely receipt of comments, and to avoid potential delays in OMB’s receipt and processing of mail sent through the U.S. Postal Service, commenters are encouraged to submit their comments to OMB via email to: OIRA_Submission@omb.eop.gov. Although commenters are encouraged to send their comments via email, commenters may also fax their comments to: 202–395–7285. VerDate Mar<15>2010 14:55 Jun 22, 2012 Jkt 226001 Commenters may also mail them to: Office of Management and Budget, Office of Information and Regulatory Affairs, New Executive Office Building, Room 10102, Washington, DC 20503. [Docket No. DHS–2012–0026] Committee Name: Homeland Security Academic Advisory Council Summer King, Statistician. [FR Doc. 2012–15414 Filed 6–22–12; 8:45 am] BILLING CODE 4162–20–P PO 00000 DEPARTMENT OF HOMELAND SECURITY Department of Homeland Security. AGENCY: Committee Management; Notice of Federal Advisory Committee Meeting. ACTION: The Homeland Security Academic Advisory Council (HSAAC) will meet on July 10, 2012 in Washington, DC. The meeting will be open to the public. SUMMARY: Frm 00044 Fmt 4703 Sfmt 4703 E:\FR\FM\25JNN1.SGM 25JNN1

Agencies

[Federal Register Volume 77, Number 122 (Monday, June 25, 2012)]
[Notices]
[Page 37912]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-15414]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Agency Information Collection Activities: Submission for OMB 
Review; Comment Request

    Periodically, the Substance Abuse and Mental Health Services 
Administration (SAMHSA) will publish a summary of information 
collection requests under OMB review, in compliance with the Paperwork 
Reduction Act (44 U.S.C. Chapter 35). To request a copy of these 
documents, call the SAMHSA Reports Clearance Officer on (240) 276-1243.

Project: Enhancing Substance Abuse Treatment Services To Address 
Hepatitis Infection Among Intravenous Drug Users Hepatitis Testing and 
Vaccine Tracking Form (OMB No. 0930-0300)--Reinstatement and Extension

    The Substance Abuse and Mental Health Services Administration's 
(SAMHSA) Center Substance Abuse Treatment (CSAT), is responsible for 
the Hepatitis Testing and Vaccine Tracking Form for the prevention of 
Viral Hepatitis in patients in designated Opioid Treatment Programs 
(OTPs). There are no changes to the form or added burden.
    This form allows SAMHSA/CSAT to collect essential Clinical 
information that will be used for quality assurance, quality 
performance and product monitoring on approximately 264 Rapid Hepatitis 
C Test kits and 10,628 doses of hepatitis vaccine (Twinrix, HAV, or 
HBV). The above kits and vaccines will be provided to designated OTPs 
serving the minority population in their communities. The information 
collected on the Form solicits and reflect the following information:

 Demographics (age, gender, ethnicity) of designated OTP site
 History (Screening) of Hepatitis C exposure
 Results of Rapid Hepatitis C Testing (Kit) and Follow-up 
information
 Service Provided (type of vaccine given) Divalent vaccine 
(Twinrix- combination HAV and HBV) or Monovalent vaccine (HAV and/or 
HBV)
 Substance Abuse Treatment Outcomes (Information regarding the 
beginning, continuing or completion of vaccination series)
 Type of Referral Services Indicated (i.e., Gastroenterology, 
TB; Mental Health, Counseling, Reproductive/Prenatal, etc.)

This program is authorized under Section 509 of the Public Health 
Service (PHS) Act [42 U.S.C. 290bb-2].
    The form increases the screening and reporting of viral hepatitis 
in high risk minorities in OTPs. The information collected allows 
SAMHSA to address the increased morbidity and mortality of hepatitis in 
minorities being treated for drug addiction.
    The SAMHSA/CSAT Hepatitis Testing and Vaccine Tracking Form 
supports quality of care, provide minimum but adequate clinical and 
product monitoring, and provide appropriate safeguards against fraud, 
waste and abuse of Federal funds.
    The table below reflects the annualized hourly burden.

----------------------------------------------------------------------------------------------------------------
   Number of  respondents
          screened              Responses/ respondent            Burden hours             Total burden hours
----------------------------------------------------------------------------------------------------------------
                50,000                            1                        0.05                       2,500
----------------------------------------------------------------------------------------------------------------

    Written comments and recommendations concerning the proposed 
information collection should be sent by July 25, 2012 to the SAMHSA 
Desk Officer at the Office of Information and Regulatory Affairs, 
Office of Management and Budget (OMB). To ensure timely receipt of 
comments, and to avoid potential delays in OMB's receipt and processing 
of mail sent through the U.S. Postal Service, commenters are encouraged 
to submit their comments to OMB via email to: OIRA_Submission@omb.eop.gov. Although commenters are encouraged to send 
their comments via email, commenters may also fax their comments to: 
202-395-7285. Commenters may also mail them to: Office of Management 
and Budget, Office of Information and Regulatory Affairs, New Executive 
Office Building, Room 10102, Washington, DC 20503.

Summer King,
Statistician.
[FR Doc. 2012-15414 Filed 6-22-12; 8:45 am]
BILLING CODE 4162-20-P